Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2014

01-07-2014 | Original Article

Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers

Authors: Markus Zollinger, Frédéric Lozac’h, Eunju Hurh, Corinne Emotte, Hounayda Bauly, Piet Swart

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2014

Login to get access

Abstract

Purpose

The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.

Methods

Six subjects received a single oral dose of 800 mg 14C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. Blood, plasma, urine, and fecal samples were collected predose, postdose in-house (days 1–22), and during 24-h visits (weekly, days 29–43; biweekly, days 57–99). Radioactivity was determined in all samples using accelerator mass spectrometry (AMS). Liquid chromatography–tandem mass spectrometry (LC–MS/MS) was used to determine concentrations of sonidegib and its main circulating metabolite in plasma. Metabolite profiles and structures were determined in pooled plasma, urine, and fecal samples using high-performance LC–AMS and LC–MS/MS, respectively.

Results

A single dose of 14C-sonidegib was well tolerated in healthy subjects. Unchanged sonidegib and total radioactivity reached peak concentration in plasma by 2 and 3 h, respectively, and demonstrated similarly long half-lives of 319 and 331 h, respectively. Absorbed sonidegib (estimated 6–7 %) was extensively distributed, and the approximate terminal volume of distribution was 2,500 L. Unchanged sonidegib and a metabolite resulting from amide hydrolysis were the major circulating components (36.4 and 15.4 % of radioactivity area under the curve, respectively). Absorbed sonidegib was eliminated predominantly through oxidative metabolism of the morpholine part and amide hydrolysis. Unabsorbed sonidegib was excreted through the feces. Metabolites in excreta accounted for 4.49 % of the dose (1.20 % in urine, 3.29 % in feces). The recovery of radioactivity in urine and feces was essentially complete (95.3 ± 1.93 % of the dose in five subjects; 56.9 % of the dose in one subject with incomplete feces collection suspected).

Conclusions

Sonidegib exhibited low absorption, was extensively distributed, and was slowly metabolized. Elimination of absorbed sonidegib occurred largely by oxidative and hydrolytic metabolism.
Literature
1.
go back to reference Teglund S, Toftgard R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805:181–208PubMed Teglund S, Toftgard R (2010) Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 1805:181–208PubMed
2.
go back to reference Pasca di Magliano M, Hebrok M (2003) Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903–911PubMedCrossRef Pasca di Magliano M, Hebrok M (2003) Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 3:903–911PubMedCrossRef
3.
go back to reference McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1–114PubMedCrossRef McMahon AP, Ingham PW, Tabin CJ (2003) Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 53:1–114PubMedCrossRef
4.
go back to reference Scales SJ, de Sauvage FJ (2009) Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30:303–312PubMedCrossRef Scales SJ, de Sauvage FJ (2009) Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 30:303–312PubMedCrossRef
5.
go back to reference Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, Han D, Liu J, Englund NP, Wang Y, Peukert S, Miller-Moslin K, Yuan J, Guo R, Matsumoto M, Vattay A, Jiang Y, Tsao J, Sun F, Pferdekamper AMC, Dodd S, Tuntland T, Maniara W, Kelleher JF III, Yao Y-M, Warmuth M, Williams J, Dorsch M (2010) Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 1:130–134PubMedCentralPubMedCrossRef Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D, Han D, Liu J, Englund NP, Wang Y, Peukert S, Miller-Moslin K, Yuan J, Guo R, Matsumoto M, Vattay A, Jiang Y, Tsao J, Sun F, Pferdekamper AMC, Dodd S, Tuntland T, Maniara W, Kelleher JF III, Yao Y-M, Warmuth M, Williams J, Dorsch M (2010) Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 1:130–134PubMedCentralPubMedCrossRef
6.
go back to reference Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, Garcia-Echeverria C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2:51ra70PubMedCentralPubMed Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, Garcia-Echeverria C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M (2010) Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2:51ra70PubMedCentralPubMed
7.
go back to reference Chen JK, Taipale J, Cooper MK, Beachy PA (2002) Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 16:2743–2748PubMedCentralPubMedCrossRef Chen JK, Taipale J, Cooper MK, Beachy PA (2002) Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 16:2743–2748PubMedCentralPubMedCrossRef
8.
go back to reference Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingham D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20:1900–1909PubMedCrossRef Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingham D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC (2014) A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20:1900–1909PubMedCrossRef
9.
go back to reference International Commission on Radiological Protection (ICRP) (2007) The 2007 recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP 37(2–4):116–117 International Commission on Radiological Protection (ICRP) (2007) The 2007 recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP 37(2–4):116–117
10.
go back to reference Zoppi U, Crye J, Song Q, Arjomand A (2007) Performance evaluation of the new AMS system at Accium Biosciences. Radiocarbon 49:171–180 Zoppi U, Crye J, Song Q, Arjomand A (2007) Performance evaluation of the new AMS system at Accium Biosciences. Radiocarbon 49:171–180
11.
go back to reference Garner RC (2000) Accelerator mass spectrometry in pharmaceutical research and development—a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205–213PubMedCrossRef Garner RC (2000) Accelerator mass spectrometry in pharmaceutical research and development—a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205–213PubMedCrossRef
12.
go back to reference Ognibene TJ, Bench G, Vogel JS, Peaslee GF, Murov S (2003) A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal Chem 75:2192–2196PubMedCrossRef Ognibene TJ, Bench G, Vogel JS, Peaslee GF, Murov S (2003) A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal Chem 75:2192–2196PubMedCrossRef
13.
go back to reference Zoppi U, Arjomand A (2010) Simultaneous AMS determination of 14C content and total carbon mass in biological samples. Nucl Instrum Methods Phys Res Sect B 268:1307–1308CrossRef Zoppi U, Arjomand A (2010) Simultaneous AMS determination of 14C content and total carbon mass in biological samples. Nucl Instrum Methods Phys Res Sect B 268:1307–1308CrossRef
14.
go back to reference Faed EM (1984) Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 15:1213–1249PubMedCrossRef Faed EM (1984) Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 15:1213–1249PubMedCrossRef
15.
go back to reference Shipkova M, Armstrong VW, Oellerich M, Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1–16PubMedCrossRef Shipkova M, Armstrong VW, Oellerich M, Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1–16PubMedCrossRef
16.
go back to reference Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, Lin ET (1993) Predictability of the covalent binding of acidic drugs in man. Life Sci 53:PL141–PL146PubMedCrossRef Benet LZ, Spahn-Langguth H, Iwakawa S, Volland C, Mizuma T, Mayer S, Mutschler E, Lin ET (1993) Predictability of the covalent binding of acidic drugs in man. Life Sci 53:PL141–PL146PubMedCrossRef
17.
go back to reference Bolze S, Bromet N, Gay-Feutry C, Massiere F, Boulieu R, Hulot T (2002) Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab Dispos 30:404–413PubMedCrossRef Bolze S, Bromet N, Gay-Feutry C, Massiere F, Boulieu R, Hulot T (2002) Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab Dispos 30:404–413PubMedCrossRef
Metadata
Title
Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers
Authors
Markus Zollinger
Frédéric Lozac’h
Eunju Hurh
Corinne Emotte
Hounayda Bauly
Piet Swart
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2468-y

Other articles of this Issue 1/2014

Cancer Chemotherapy and Pharmacology 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine